• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. FDA approves Daraxonrasib this year?
FDA approves Daraxonrasib this year?

FDA approves Daraxonrasib this year?

0.5% (24h)Health & MedicineOne-Off6m
PolymarketPolymarketComprobar disponibilidadSin KYC2% de comisión
Probabilidad implícita actual
Sí
Sí 71%+0.0%
Calidad del mercado

24 / 100

Baja calidad
Volumen 24h

0 €

Liquidez

1,6 mil €

Baja liquidez
Compra / Venta

67.0% / 75.0%

Spread

11.9%

Spread amplio
Cambio 7d

+3.0%

Datos de mercado

Actualizado hace 5 minutos

13 may 26, 21:5431 dic 26, 0:00

Tendencias

Resultado24hProbabilidad

Resultado elegido

Yes71%

Reglas

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sí: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sí: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sí: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Activos en estos temas

BitcoinBTC$62,853.43+2.49%EthereumETH$1,658.07+1.88%SolanaSOL$65.29+1.88%DogecoinDOGE$0.0849+1.67%XRPXRP$1.12+0.68%BNBBNB$596.70+1.82%

Noticias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Reglas

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs